scispace - formally typeset
S

Steven J. Nurkin

Researcher at Roswell Park Cancer Institute

Publications - Ā 62
Citations - Ā 5064

Steven J. Nurkin is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Colorectal cancer & Neoadjuvant therapy. The author has an hindex of 20, co-authored 57 publications receiving 3350 citations. Previous affiliations of Steven J. Nurkin include City of Hope National Medical Center & New York Hospital Queens.

Papers
More filters
Journal ArticleDOI

Rectal cancer, version 2.2018 clinical practice guidelines in Oncology

TL;DR: The NCCN Clinical Practice Guidelines in Oncology for Rectal Cancer address diagnosis, staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, disease surveillance, and survivorship in patients with rectal cancer.
Journal ArticleDOI

NCCN GuidelinesĀ® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

Al B. Benson, +35 more
TL;DR: The NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib are summarized.
Journal ArticleDOI

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Al B. Benson, +38 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section as discussed by the authors.
Journal ArticleDOI

Rectal cancer, version 6.2020: Featured updates to the NCCN guidelines

Al B. Benson, +70 more
TL;DR: These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer.